v3.26.3
Note 13 - Capital Stock (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 13, 2026
Sep. 30, 2026
May 31, 2026
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Oct. 31, 2024
Jun. 30, 2023
Common Stock, Shares Authorized (in shares)   600,000,000   600,000,000   600,000,000   600,000,000    
Common Stock, Par or Stated Value Per Share (in dollars per share)   $ 0.0001   $ 0.0001   $ 0.0001   $ 0.0001    
Preferred Stock, Shares Authorized (in shares)   1,000,000   1,000,000   1,000,000   1,000,000    
Preferred Stock, Par or Stated Value Per Share (in dollars per share)   $ 0.0001   $ 0.0001   $ 0.0001   $ 0.0001    
Common Stock, Shares, Issued (in shares)   14,213,981   14,213,981   14,213,981   10,849,974    
Preferred Stock, Shares Issued (in shares)   0   0   0   0    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)   7,910,247   7,910,247   7,910,247   6,696,914    
Common Stock, Shares, Outstanding (in shares)   14,213,981   14,213,981   14,213,981   10,849,974    
Preferred Stock, Shares Outstanding (in shares)   0   0   0   0    
January 2026 Public Equity Offering [Member]                    
Stock Issued During Period, Shares, New Issues (in shares) 928,333                  
Proceeds from Issuance or Sale of Equity $ 6,000,000                  
Payments for Commissions 400,000                  
Payments of Stock Issuance Costs 300,000                  
Fair Value of Equity Issued Exceeding Offering Proceeds Amount 4,600,000                  
January 2026 Public Equity Offering [Member] | Certain Directors, Executive Officers, and Affiliated Entities [Member]                    
Proceeds from Issuance or Sale of Equity $ 300,000                  
Underwriting Agreement [Member]                    
Stock Issued During Period, Shares, New Issues (in shares)   1,219,513 1,000,000              
Payments for Commissions     $ 500,000              
Payments of Stock Issuance Costs     $ 100,000              
Shares Issued, Price Per Share (in dollars per share)   $ 3.28 $ 7 $ 3.28   $ 3.28        
Proceeds from Issuance of Common Stock   $ 4,000,000 $ 7,000,000 $ 4,000,000   $ 17,000,000        
Underwriting Agreement [Member] | Certain Directors, Executive Officers, and Affiliated Entities [Member]                    
Proceeds from Issuance of Common Stock   $ 2,100,000                
ATM Facility [Member]                    
Stock Issued During Period, Shares, New Issues (in shares)       216,161 757,875 216,161 2,095,070      
Payments for Commissions       $ 15,000 $ 100,000 $ 15,000 $ 100,000      
Proceeds from Issuance of Common Stock       $ 1,000,000 $ 3,300,000 $ 1,000,000 $ 8,400,000      
Avenue Warrants 2023 [Member]                    
Class of Warrant or Right, Exercised During Period (in shares)           0   0    
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) [1]   $ 4.6014   $ 4.6014   $ 4.6014        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) [1]   150,000   150,000   150,000   150,000    
Tranche A Warrant [Member]                    
Class of Warrant or Right, Exercised During Period (in shares)               0    
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)                   1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)   $ 22 [2]   $ 22 [2]   $ 22 [2]       $ 22
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)   0 [2]   0 [2]   0 [2]   2,500,000 [2]   2,500,000
Tranche B Warrant [Member]                    
Class of Warrant or Right, Exercised During Period (in shares)           0   0    
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)                   1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) [3]   $ 30   $ 30   $ 30        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) [3]   2,500,000   2,500,000   2,500,000   2,500,000    
The 2024 Common Warrants [Member]                    
Class of Warrant or Right, Exercised During Period (in shares)           0        
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)                 1  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)                 $ 4.82  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                 1,546,914  
Series A Warrants [Member]                    
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) 1.2                  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 6 $ 6 [4]   $ 6 [4]   $ 6 [4]        
Warrants and Rights Outstanding, Term (Year) 3 years                  
Class of Warrant or Right, Redemption Price Upon Nonexercise (in dollars per share) $ 0.01                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 1,114,000 1,114,000 [4]   1,114,000 [4]   1,114,000 [4]   0 [4]    
Series B Warrants [Member]                    
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) 2.8                  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 6 $ 6 [5]   $ 6 [5]   $ 6 [5]        
Warrants and Rights Outstanding, Term (Year) 5 years                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 2,599,333 2,599,333 [5]   2,599,333 [5]   2,599,333 [5]   0 [5]    
[1] We issued the 2023 Avenue Warrant pursuant to a loan with Avenue (see Note 12). As of September 30, 2026 and December 31, 2025, the 2023 Avenue Warrant had not been exercised.
[2] We issued the Tranche A Warrants in a June 2023 public equity offering. Each Tranche A Warrant was exercisable for one share of our common stock. The Tranche A Warrants expired unexercised on June 16, 2026.
[3] We issued warrants in a June 2023 public equity offering (the “Tranche B Warrants”). Each Tranche B Warrant is exercisable for one share of our common stock. The Tranche B Warrants expire on the earlier of (i) 60 days following the date of our public announcement that an NDA for CNM-Au8 has been approved by the FDA, or (ii) June 16, 2030. As of September 30, 2026 and December 31, 2025, no Tranche B Warrants had been exercised.
[4] We issued the Series A Warrants in a January 2026 public equity offering. Each Series A Warrant is exercisable for 1.2 shares of our common stock. The Series A Warrants expire three years from issuance unless, if on or after the first trading day immediately following the Series A Price Measurement Date, the closing price of our common stock is in-the-money, then we shall have the right, for a period of seven business days (such seventh day, the “Call Date”) following such trading date, to redeem or call for cancellation all or any portion of the Series A Warrants for which a notice of exercise has not yet been delivered for consideration equal to $0.01 per share (the “Redemption Price”). Any portion not exercised by 5:00 p.m. Eastern Time on the Call Date shall be automatically redeemed by us for the Redemption Price and shall thereafter be null and void. As of September 30, 2026, no Series A Warrants had been exercised.
[5] We issued the Series B Warrants in a January 2026 public equity offering. Each Series B Warrant is exercisable for 2.8 shares of our common stock. The Series B Warrants expire five years from issuance unless, if on or after the first trading day immediately following the Series B Price Measurement Date, the closing price of our common stock is in-the-money, then we shall have the right, for a period of seven business days following such trading date, to redeem or call for cancellation all or any portion of the Series B Warrants for which a notice of exercise has not yet been delivered for the Redemption Price. Any portion not exercised by 5:00 p.m. Eastern Time on the Call Date shall be automatically redeemed by us for the Redemption Price and shall thereafter be null and void. As of September 30, 2026, no Series B Warrants had been exercised.